Nursing Pharmacology: Drugs that Influence Coagulation
Anticoagulant Drugs: Pharmacology |
Antithrombotic Agents- Antiplatelet Drugs Pharmacological Management of Thrombosis
|
Abnormal states of hemostasis
Bleeding (impaired hemostasis)
Thrombus formation (stimulated hemostasis)
Thrombogenesis: Sequence and Characteristics
Normal:
Normal vascular endothelial cells:
Not thrombogenic (platelet/clotting factors do not adhere)
|
|
|
|
|
|
Immediate response: vasospasm
Platelet adherence to damaged epithelium (binds to collagen) referred to as platelet adhesion. (collagen-platelet membrane glycoprotein Ia receptor interaction)
Platelets binding to each other: platelet aggregation
Platelets form a gelatinous mass (losing individual membranes): viscous metamorphosis. → platelet plug (temporary cessation of bleeding)
Platelet plug -- reinforcement by fibrin
Damaged vessel .→ exposed collagen + platelet content released
Platelet degranulation releases aggregating substances:
ADP
TXA2
5-HT
Local thrombin production:
Platelet ADP release (ADP inducer of platelet aggregation)
Prostaglandin synthesis (derived from platelet membrane arachidonic acid)
Thrombogenesis/vasoconstriction: thromboxane A2 , TXA2)
Thrombogenesis inhibitor: prostacyclin
Where: high-pressure arteries
Circulating platelet adherence to regions of abnormal epithelium
Aggregated-platelet thrombus→ reduced flow
Red thrombus forms around white thrombus nidus
Forms either secondary to white thrombus or de novo -- low pressure veins
Thrombus forms a fibrin network longer tail entraps red cells)
Fibrin tail may detach forming emboli which may travel to pulmonary arteries
Blood Coagulation-- soluble fibrinogen → insoluble fiber
Fibrinogen (factor I; soluble fiber precursor) substrate for thrombin (enzyme, factor IIa)→fibrin clot
Thrombin formed from activation of its zymogen, prothrombin (factor II)
Prothrombin (factor II): bound by a calcium to platelet phospholipid (PL); activated factor X (Xa) + activated factor Va converts prothrombin (factor II) → circulating thrombin
Tissue factor (TF) + factor VII
Tissue factor pathway inhibitor (TFPI)
Endogenous anticoagulants: protein C, protein S: down-regulation of blood clotting amplification by proteolysis factors Va, VIIIa and IXa.
Oral anticoagulants: inhibits clotting factor synthesis (e.g.: heparin inhibits activity of certain activated factors.)
Classical Blood Coagulation Pathway
|
|
Factor/Component |
also called |
Target |
I |
Fibrinogen |
|
II |
Prothrombin |
Heparin (IIa); Warfarin (synthesis) |
III |
Tissue Thromboplastin |
|
IV |
Calcium |
|
V |
Proaccelerin |
|
VII |
Proconvertin |
Heparin (VIIa); Warfarin (synthesis) |
VIII |
Antihemophilic globulin (AHG) |
|
IX |
Christmas factor, plasma thromboplastin component (PTC) |
Heparin (IXa); Warfarin (synthesis) |
X |
Stuart-Prower factor |
Heparin (IXa); Warfarin (synthesis) |
XI |
Plasma thromboplastin antecedent (PTA) |
|
XII |
Hageman factor |
|
XIII |
Fibrin-stabilizing factor |
|
Proteins C and S |
------- |
Warfarin (synthesis) |
Plasminogen |
------- |
Thrombolytic enzymes, aminocaproic acid |
Primary Reference: O'Reilly, R.A. Drugs Used in Disorders of Coagulation, in Basic and Clinical Pharmacology, (Katzung, B. G., ed) Appleton-Lange, 1998, pp 916-940
Handlin, R.I. Bleeding and Thrombosis, In Harrison's Principles of Internal Medicine 14th edition, (Isselbacher, K.J., Braunwald, E., Wilson, J.D., Martin, J.B., Fauci, A.S. and Kasper, D.L., eds) McGraw-Hill, Inc (Health Professions Division), 1998, pp 339-344.